Literature DB >> 25309068

Biomarkers for pancreatic cancer: recent achievements in proteomics and genomics through classical and multivariate statistical methods.

Emilio Marengo1, Elisa Robotti1.   

Abstract

Pancreatic cancer (PC) is one of the most aggressive and lethal neoplastic diseases. A valid alternative to the usual invasive diagnostic tools would certainly be the determination of biomarkers in peripheral fluids to provide less invasive tools for early diagnosis. Nowadays, biomarkers are generally investigated mainly in peripheral blood and tissues through high-throughput omics techniques comparing control vs pathological samples. The results can be evaluated by two main strategies: (1) classical methods in which the identification of significant biomarkers is accomplished by monovariate statistical tests where each biomarker is considered as independent from the others; and (2) multivariate methods, taking into consideration the correlations existing among the biomarkers themselves. This last approach is very powerful since it allows the identification of pools of biomarkers with diagnostic and prognostic performances which are superior to single markers in terms of sensitivity, specificity and robustness. Multivariate techniques are usually applied with variable selection procedures to provide a restricted set of biomarkers with the best predictive ability; however, standard selection methods are usually aimed at the identification of the smallest set of variables with the best predictive ability and exhaustivity is usually neglected. The exhaustive search for biomarkers is instead an important alternative to standard variable selection since it can provide information about the etiology of the pathology by producing a comprehensive set of markers. In this review, the most recent applications of the omics techniques (proteomics, genomics and metabolomics) to the identification of exploratory biomarkers for PC will be presented with particular regard to the statistical methods adopted for their identification. The basic theory related to classical and multivariate methods for identification of biomarkers is presented and then, the most recent applications in this field are discussed.

Entities:  

Keywords:  Biomarker identification; Multivariate analysis; Pancreatic cancer; Principal component analysis; Ranking principal component analysis

Mesh:

Substances:

Year:  2014        PMID: 25309068      PMCID: PMC4188889          DOI: 10.3748/wjg.v20.i37.13325

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  55 in total

Review 1.  Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.

Authors:  Nigel B Jamieson; C Ross Carter; Colin J McKay; Karin A Oien
Journal:  Clin Cancer Res       Date:  2011-03-28       Impact factor: 12.531

2.  Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.

Authors:  Ian McCaffery; Yanyan Tudor; Hongjie Deng; Rui Tang; Samuel Suzuki; Sunita Badola; Hedy L Kindler; Charles S Fuchs; Elwyn Loh; Scott D Patterson; Li Chen; Jennifer L Gansert
Journal:  Clin Cancer Res       Date:  2013-06-05       Impact factor: 12.531

3.  Low expression of junctional adhesion molecule A is associated with metastasis and poor survival in pancreatic cancer.

Authors:  Dominic Fong; Gilbert Spizzo; Manfred Mitterer; Andreas Seeber; Michael Steurer; Guenther Gastl; Ines Brosch; Patrizia Moser
Journal:  Ann Surg Oncol       Date:  2012-05-02       Impact factor: 5.344

4.  Study of proteomic changes associated with healthy and tumoral murine samples in neuroblastoma by principal component analysis and classification methods.

Authors:  Emilio Marengo; Elisa Robotti; Pier Giorgio Righetti; Natascia Campostrini; Jennifer Pascali; Mirko Ponzoni; Mahmoud Hamdan; Hubert Astner
Journal:  Clin Chim Acta       Date:  2004-07       Impact factor: 3.786

5.  Applying proteomic-based biomarker tools for the accurate diagnosis of pancreatic cancer.

Authors:  Kyoko Kojima; Senait Asmellash; Christopher A Klug; William E Grizzle; James A Mobley; John D Christein
Journal:  J Gastrointest Surg       Date:  2008-08-15       Impact factor: 3.452

6.  The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray.

Authors:  Tasneem H Patwa; Chen Li; Laila M Poisson; Hye-Yeung Kim; Manoj Pal; Debashis Ghosh; Diane M Simeone; David M Lubman
Journal:  Electrophoresis       Date:  2009-06       Impact factor: 3.535

7.  Semi-supervised methods to predict patient survival from gene expression data.

Authors:  Eric Bair; Robert Tibshirani
Journal:  PLoS Biol       Date:  2004-04-13       Impact factor: 8.029

8.  A power law global error model for the identification of differentially expressed genes in microarray data.

Authors:  Norman Pavelka; Mattia Pelizzola; Caterina Vizzardelli; Monica Capozzoli; Andrea Splendiani; Francesca Granucci; Paola Ricciardi-Castagnoli
Journal:  BMC Bioinformatics       Date:  2004-12-17       Impact factor: 3.169

9.  Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis.

Authors:  Stephanie T Chang; Jacob M Zahn; Joe Horecka; Pamela L Kunz; James M Ford; George A Fisher; Quynh T Le; Daniel T Chang; Hanlee Ji; Albert C Koong
Journal:  J Transl Med       Date:  2009-12-11       Impact factor: 5.531

10.  A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers.

Authors:  Jordan M Winter; Laura H Tang; David S Klimstra; Murray F Brennan; Jonathan R Brody; Flavio G Rocha; Xiaoyu Jia; Li-Xuan Qin; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; William R Jarnagin; Eileen M O'Reilly; Peter J Allen
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

View more
  11 in total

1.  A Prospective Targeted Serum Metabolomics Study of Pancreatic Cancer in Postmenopausal Women.

Authors:  Li Jiao; Suman Maity; Cristian Coarfa; Kimal Rajapakshe; Liang Chen; Feng Jin; Vasanta Putluri; Lesley F Tinker; Qianxing Mo; Fengju Chen; Subrata Sen; Haleh Sangi-Hyghpeykar; Hashem B El-Serag; Nagireddy Putluri
Journal:  Cancer Prev Res (Phila)       Date:  2019-02-05

Review 2.  Proteomic approaches to identify circulating biomarkers in patients with abdominal aortic aneurysm.

Authors:  Dan Bylund; Anders E Henriksson
Journal:  Am J Cardiovasc Dis       Date:  2015-09-15

3.  Endoscopic ultrasound pin-points the precision medicine for pancreatic cancer.

Authors:  Ping Zhu; Siyu Sun
Journal:  Endosc Ultrasound       Date:  2016 Jan-Feb       Impact factor: 5.628

4.  Metabolomics approaches in pancreatic adenocarcinoma: tumor metabolism profiling predicts clinical outcome of patients.

Authors:  S Battini; F Faitot; A Imperiale; A E Cicek; C Heimburger; G Averous; P Bachellier; I J Namer
Journal:  BMC Med       Date:  2017-03-16       Impact factor: 8.775

5.  Prognostic value of pre-treatment peripheral blood markers in pancreatic ductal adenocarcinoma and their association with S100A4 expression in tumor tissue.

Authors:  Hua Li; Xiangdong Tian; Yong Xu; Yi Pan; Yubei Huang; Dejun Zhou; Zhenguo Song
Journal:  Oncol Lett       Date:  2019-09-05       Impact factor: 2.967

6.  Increased SPHK1 and HAS2 Expressions Correlate to Poor Prognosis in Pancreatic Cancer.

Authors:  Mengsi Yu; Kainan Zhang; Song Wang; Li Xue; Zhaoyun Chen; Ning Feng; Conghua Ning; Lijuan Wang; Jing Li; Boke Zhang; Changcheng Yang; Zhaoxia Zhang
Journal:  Biomed Res Int       Date:  2021-01-06       Impact factor: 3.411

7.  Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.

Authors:  Kazufumi Honda; Michimoto Kobayashi; Takuji Okusaka; Jo Ann Rinaudo; Ying Huang; Tracey Marsh; Mitsuaki Sanada; Yoshiyuki Sasajima; Shoji Nakamori; Masashi Shimahara; Takaaki Ueno; Akihiko Tsuchida; Naohiro Sata; Tatsuya Ioka; Yohichi Yasunami; Tomoo Kosuge; Nami Miura; Masahiro Kamita; Takako Sakamoto; Hirokazu Shoji; Giman Jung; Sudhir Srivastava; Tesshi Yamada
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

8.  Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma.

Authors:  Sari F Alhasan; Beate Haugk; Laura F Ogle; Gary S Beale; Anna Long; Alastair D Burt; Dina Tiniakos; Despina Televantou; Fareeda Coxon; David R Newell; Richard Charnley; Helen L Reeves
Journal:  Br J Cancer       Date:  2016-08-25       Impact factor: 7.640

9.  Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer.

Authors:  Tatsuya Kitagawa; Keisuke Taniuchi; Makiko Tsuboi; Masahiko Sakaguchi; Takuhiro Kohsaki; Takehiro Okabayashi; Toshiji Saibara
Journal:  Mol Oncol       Date:  2018-11-15       Impact factor: 6.603

10.  Immune Signature Against Plasmodium falciparum Antigens Predicts Clinical Immunity in Distinct Malaria Endemic Communities.

Authors:  Carla Proietti; Lutz Krause; Angela Trieu; Daniel Dodoo; Ben Gyan; Kwadwo A Koram; William O Rogers; Thomas L Richie; Peter D Crompton; Philip L Felgner; Denise L Doolan
Journal:  Mol Cell Proteomics       Date:  2019-10-28       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.